Dr Aude Chapuis is head of a laboratory focusing on the development a translational pipeline designed to improve T cell receptor (TCR) gene therapy. This spans target identification, generation of high-affinity TCRs, cell process methodologies to translate these constructs into effective products for patients, clinical trial development and execution, and sophisticated high dimensional immune-monitoring to maximize the information that can be derived from each treated patient. A non-exhaustive list of diseases being targeted by the lab include virally-driven tumors (targeting Merkel-cell polyoma virus antigens in Merkel cell carcinoma), solid tumors (targeting the cancer-testis antigens in non-small cell lung cancer, triple negative breast cancer, and bladder cancers; and targeting Wilms’ tumor antigen 1 [WT1] in thoracic and gynecological cancers), and leukemias (targeting two epitopes of WT1 in acute myeloid leukemia). The lab is embedded within a highly collaborative network to implement these translational strategies including investigators in basic science, oncology disease-specific clinicians, and cancer immunology labs. Additionally, Dr Chapuis is an oncologist and attends in the Bone marrow transplant and Immunotherapy services.